Book a Demo

Please select a preferred date(s) and time(s):

    Contact Sales

      By clicking "Submit" you agree to our Privacy Policy

      CertiScan®: Adherence Matters

      USE CASE

      New PK and PD Analysis Options

      Unlock a new level of confidence in your data.

      Get on-demand adherence data and derived insights across the entire participant population. Conduct unprecedented data filtering, analysis, and reporting based on accurate adherence data. Gain assurance that studies are on track to meet their endpoints.


      De-Noise the Analysis
      denoise the analysis
      Non-adherence is a primary source of noise, making it mor difficult to discern a therapeutic effect. Measuring adherence lets you apply techniques for sanitizing the data, making therapeutic signals clearer if one exists.
      Model Plasma Levels
      Our adherence data has been shown to correlate extremely strongly with drug plasma concentrations. This lets your teams create more complete physiological models of each participant or conduct fewer blood draws: using adherence to infer plasma levels more completely, and therefore requiring fewer site visits.
      Stratify by Adherence
      Our software includes powerful tools for sorting and filtering participants based on numerous adherence dimensions. This enables you to create segments and cohorts based on the criteria for your adaptive protocols.

      Specific Benefits

      Fewer Participants, Same Power

      Basing final PK and PD analysis on a more selective group of highly adherent participant can yield the same power despite having a smaller number. This selective group can be achieved either by adapting enrollment or by stratifying data post hoc.

      Adjust Outcome Measures

      Apply statistical techniques such as covariance analysis to see if there is an adherence effect and use our adherence data as a parameter, in order to better understand efficacy, side effects, and more.

      Better Phase III Go-or-No Decisions

      Once safety and tolerability have been assessed, adherence data can support the go-or-no decision. The costs of equipping a phase II trial with our solution are minimal compared to the expenses and resource commitments of a phase III trial.

      Potential for Fewer Blood Draws

      For path-setting trials: use adherence as a measure of plasma concentration, in order to reduce (but never replace) blood draw activities.

      Reduce Post market Risk

      Conclusions regarding the therapeutic dosage and side effects are often based on idealized adherence levels rather than real world levels. This can distort trial results and introduce risks that are only discovered post-market.

      Fewer Participants, Same Power

      Our solutions are low-cost insurance measure against “just missing” a primary endpoint. Once data is stratified by adherence, significance can emerge and save an enormously expensive trial. Read below to learn more.

      Learn More about the Products
      that Power our Solutions



      The original smart blister package. Breaking a blister records the time and location (i.e. “8:00 a.m.” and “Day 1, Morning”). Med-ic® can be customized to work with any blister design and dose pattern.


      The superior smart cap. Unscrewing and removing the eCap™ records the opening time. Several diameter and threading options are available to fit all common bottle types.

      CertiScan® Platform

      Consumer-quality software for clinical trials. Securely store, analyze, and action the data from smart packaging and other adherence devices. The CertiScan® Platform includes web portals, mobile apps, developer tools, and a secure, central cloud.

      Did You Know?

      Missing doses, taking extra doses, or taking doses at inconsistent times make it challenging to keep drug plasma levels within the desired therapeutic window. This can result in ineffectiveness due to inadequate plasma levels, or side effects due to elevated levels. Both have serious implications for the clinical trial decision-making process.
      A phase II trial showed no difference between treatment and placebo groups according to the primary outcome analysis. But when the subjects were stratified by adherence, there was a highly significant treatment effect for the participants who actually took the drug as prescribed. The drug was subject to further assessment.
      treatment assessment
      FDA approved
      The FDA, through its Critical Path initiative, has expressed an interest in the application of new tools to clinical trials. Advanced PK/PD analysis based on medication adherence monitoring can be an integral part of this process.


      Our experts have modelled the relationship between statistical power, sample size and medication adherence.
      Their findings? For every 1% adherence increase, there can be a 2% reduction in trial size (N) while holding statistical power constant.
      Considering that many trials currently only reach 50% adherence, there’s lots of room for improvement – and tremendous ROI.

      Direct Savings from Reduced N

      Processing a participant is expensive. Requiring a smaller sample size could amount to millions of dollars in savings.
      Drug Development

      Additional Weeks of Patent Protection

      Smaller N means a faster trial, potentially by months. This could amount to tens of millions of dollars in additional revenue.

      Additional Weeks of Patent Protection

      Smaller N means a faster trial, potentially by months. This could amount to tens of millions of dollars in additional revenue.

      Recent Articles

      Scientific Publications | 16 May 2024

      Independent Study finds eCap™…

      Read More
      Press Releases | 6 May 2024

      Information Mediary Corp. and…

      PRESS RELEASE May 6, 2024 – New York, NY — Information Mediary Corp (IMC)…

      Read More
      Blog | 5 May 2024

      Welcome to the new…

      We are thrilled to unveil our revamped website! As you explore our new digital…

      Read More
      Case Studies | 5 May 2024

      Evaluating Hepatitis C Treatment…

      Overview Direct-Acting Antiviral (DAA) therapy is an effective treatment for hepatitis C. However DAA…

      Read More
      Whitepapers | 5 May 2024

      Driving Adherence With Smart…

      Read More
      Press Releases | 4 May 2024

      IMC introduces CertiScan® 2.0

      Att: Health Tech Desk FOR IMMEDIATE RELEASE April 28, 2021 New York, NY Contact:…

      Read More

      Let's Talk

      Our mission is to create adherence-focused technologies that enable safer, faster, more efficient, and more innovative clinical research. There’s an IMC solution that will transform your next trial. Don’t wait, start the conversation with our team now. We’ll reach out in order to:
      • Deeply understand your particular needs.
      • Explore how Med-ic®, eCap™, and CertiScan®, can benefit your study.
      • Work collaboratively to prepare a specific solution that will exceed your expectations.

      Connect with Us

        By clicking "Submit" you agree to our Privacy Policy